Addyi Cost in New Mexico 2026: Prices, Insurance, Medicaid, and Compounded Alternatives

What Is the Cash Price for Addyi in New Mexico in 2026?

Brand-name Addyi retails at approximately $880 per month across New Mexico pharmacies in 2026, matching the national list price set by Sprout Pharmaceuticals. That figure buys 30 tablets of flibanserin 100 mg. No generic version has received FDA approval, so every patient paying cash faces that same ceiling unless they use a manufacturer card, a discount program, or a compounding pharmacy.

Flibanserin was approved by the FDA on August 18, 2015, under the brand name Addyi, making it the first pharmacologic treatment cleared specifically for hypoactive sexual desire disorder (HSDD) in premenopausal women. The FDA approval label carries a Risk Evaluation and Mitigation Strategy (REMS) requirement because of a clinically significant interaction with alcohol that produces severe hypotension and syncope. Prescribers, pharmacies, and patients must all enroll in the Addyi REMS program before a prescription can be dispensed. That enrollment requirement adds a layer of friction that some New Mexico pharmacies are not set up to handle, which can push patients toward mail-order or telehealth platforms that specialize in sexual health.

The $880 figure is the manufacturer's suggested retail price. Individual pharmacy acquisition costs vary slightly. GoodRx and similar coupon aggregators occasionally list prices between $820 and $870 at chains such as Walgreens and CVS locations in Albuquerque and Santa Fe, but savings at that range are marginal. For most uninsured or underinsured New Mexico patients, the relevant comparison is not between retail pharmacies but between brand Addyi and compounded flibanserin.

Does New Mexico Medicaid Cover Addyi?

New Mexico Medicaid does not cover Addyi. The drug is excluded from the Centennial Care formulary, the managed-care framework that coordinates benefits for roughly 900,000 New Mexico Medicaid enrollees. Patients enrolled in Presbyterian Centennial Care, Molina Healthcare of New Mexico, or United Healthcare Community Plan of New Mexico cannot obtain Addyi through those plans regardless of medical necessity documentation in 2026.

This exclusion is not unique to New Mexico. Medicaid programs in most states treat HSDD pharmacotherapy as a low-priority or non-covered category. The FDA label documents the approved indication clearly, but formulary decisions rest with each state's Drug Utilization Review board, and New Mexico's board has not added flibanserin to the preferred drug list. Patients who believe their case warrants an exception may file a prior authorization appeal through their specific managed-care organization, though approval rates for non-formulary HSDD drugs remain very low based on available formulary data. Physicians should document severity scores, duration of symptoms, and any prior non-pharmacologic interventions when preparing an appeal.

Women enrolled in the New Mexico Human Services Department's Medicaid Expansion population (adults aged 19 to 64 with incomes up to 138% of the federal poverty level) are similarly excluded, as are patients in the State Coverage Insurance bridge program. No state pharmaceutical assistance program in New Mexico specifically lists flibanserin as a covered medication.

Which Private Insurance Plans Cover Addyi in New Mexico?

Private coverage for Addyi in New Mexico is inconsistent and requires prior authorization on virtually every commercial plan. Blue Cross Blue Shield of New Mexico, Presbyterian Health Plan, and New Mexico Health Connections each manage their own formularies, and flibanserin's tier placement changes with annual contract cycles.

The BEGONIA trial, published in the Journal of Sexual Medicine in 2014 (N=1,378), demonstrated that flibanserin 100 mg at bedtime produced a statistically significant increase in the number of satisfying sexual events over 24 weeks compared with placebo (P<0.001). That evidence base supports the FDA-approved indication, but insurance medical necessity criteria often additionally require documented failure of psychotherapy or couples counseling before approving a drug claim. Physicians filing prior authorization requests in New Mexico should specifically reference FDA-approved prescribing information and cite objective HSDD diagnostic criteria per the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5).

Employers who self-insure under ERISA plans, common among New Mexico's larger employers in the energy, government, and healthcare sectors, may have separate formulary rules that differ from the retail plan branded by a carrier. Patients should request their Summary Plan Description and the pharmacy benefit manager's (PBM) specific prior authorization criteria in writing. Express Scripts, CVS Caremark, and OptumRx each have national clinical criteria documents available to enrollees upon request.

When prior authorization is approved, typical cost sharing places Addyi on a specialty or Tier 3/4 position with a co-pay ranging from $50 to $150 per month after deductible. Out-of-pocket maximums under the ACA limit annual exposure, but patients may face high early costs before that cap is reached.

Is Compounded Flibanserin Legal in New Mexico?

Compounded flibanserin is legal in New Mexico when prepared by a state-licensed 503A pharmacy operating under a valid patient-specific prescription. This is a meaningful access pathway. A licensed New Mexico compounding pharmacy can prepare flibanserin capsules or other formulations for individual patients at a price that may be substantially below $880 per month.

Section 503A of the Federal Food, Drug, and Cosmetic Act governs traditional compounding pharmacies that produce patient-specific preparations. The FDA's guidance on compounded drugs distinguishes 503A pharmacies from 503B outsourcing facilities. Under 503A, a licensed practitioner writes a prescription for a specific patient, a licensed pharmacist compounds the drug, and it does not cross state lines without additional regulatory requirements. New Mexico pharmacies holding a current New Mexico Board of Pharmacy compounding license may fill such prescriptions.

Because flibanserin is an FDA-approved drug, federal compounding law prohibits commercial-scale compounding of it by 503B outsourcing facilities for routine distribution. However, 503A compounding for individual patients is explicitly permitted under the law when there is a valid prescription, the drug is not on the FDA's "difficult to compound" list, and the compounding pharmacist meets state licensing standards. As of 2025 to 2026, flibanserin does not appear on the FDA's list of drug products that present demonstrable difficulties for compounding, which supports the legality of 503A preparation in New Mexico.

Patients should verify that any online compounding pharmacy serving New Mexico residents holds a current New Mexico non-resident pharmacy license or is physically located in-state. Telehealth platforms offering compounded flibanserin should be able to provide the compounding pharmacy's NABP (National Association of Boards of Pharmacy) number on request.

Compounded flibanserin cost varies by pharmacy. Some telehealth platforms offer compounded flibanserin subscriptions starting under $100 per month for New Mexico patients, though prices depend on formulation and shipping fees. The cost advantage over brand Addyi at $880 per month is substantial.

Can New Mexico Patients Get Addyi via Telehealth?

Telehealth prescribing of Addyi is available to New Mexico residents, and it has become the primary access route for many patients outside of Albuquerque. New Mexico follows the federal framework for telehealth prescribing of non-controlled substances. Flibanserin is not a controlled substance, so audio-video or even asynchronous telehealth encounters can support a valid prescription in most cases under New Mexico law.

The prescribing clinician must still enroll in the Addyi REMS program before transmitting the prescription. Patients must also complete the Addyi REMS patient enrollment form, which attests to understanding the alcohol interaction risk. The REMS documentation requirement applies regardless of whether the encounter is in-person or remote.

Several national telehealth platforms, including those focused specifically on women's sexual health, now list New Mexico as a covered state. These platforms typically employ physicians or nurse practitioners licensed in New Mexico who can conduct a synchronous telehealth visit, assess HSDD using a validated instrument such as the Female Sexual Function Index (FSFI) or the Decreased Sexual Desire Screener (DSDS), and transmit a prescription to a pharmacy of the patient's choice.

The FSFI is a 19-item, validated self-report measure covering sexual desire, arousal, lubrication, orgasm, satisfaction, and pain domains, with a total score of 26.55 or below indicating sexual dysfunction. Telehealth clinicians using the FSFI generate documentable clinical evidence of HSDD severity, which supports both prescribing decisions and insurance appeals.

New Mexico's Telehealth Act (NMSA 1978, Section 24-25-1 through 24-25-8) requires that telehealth services meet the same standard of care as in-person services. Clinicians should conduct a thorough medication history, including any CNS depressants or CYP2C19 inhibitors, before prescribing flibanserin. Fluconazole, for example, is a potent CYP2C19 inhibitor; concurrent use with flibanserin is contraindicated per the FDA label due to a five-fold increase in flibanserin exposure.

How the Sprout Pharmaceuticals Savings Card Works in New Mexico

Sprout Pharmaceuticals offers a patient savings card that can reduce out-of-pocket cost for commercially insured patients. Eligible patients pay as little as $25 per month for the first fill and up to $99 per month thereafter under the program terms as of 2025 to 2026. New Mexico residents with commercial insurance (not Medicaid, not Medicare) may qualify.

The savings card does not apply to government-funded insurance. Patients enrolled in New Mexico Medicaid, Medicare Part D, or any state or federal program cannot use the Sprout savings card for those prescriptions. This is a legal restriction under federal anti-kickback rules, not a program limitation specific to New Mexico.

To activate the card, patients visit the Addyi official website, complete the REMS enrollment, and download or print the savings card. The card is presented at the dispensing pharmacy alongside the prescription. Not every New Mexico pharmacy is REMS-enrolled; patients should confirm REMS enrollment with the pharmacy before attempting to fill the prescription.

The card has a monthly cap and an annual maximum benefit. Patients whose insurance applies a specialty tier co-pay above the card's coverage ceiling will still owe the difference. Reviewing the specific benefit terms each plan year is the appropriate step before assuming coverage amounts.

What HSDD Diagnosis Criteria Must Be Met to Prescribe Flibanserin?

Flibanserin is FDA-approved only for acquired, generalized HSDD in premenopausal women. Prescribers must confirm the diagnosis before writing the prescription, and payers require documented evidence of diagnosis in prior authorization requests.

The DSM-5 defines female sexual interest/arousal disorder (FSIAD) as the DSM-level diagnosis that most closely maps to HSDD, requiring at least three of six specified symptoms for a minimum of six months and causing clinically significant distress. Clinicians should document distress explicitly. Absence of distress disqualifies a patient from both the FDA-approved indication and insurance coverage. The ACOG Committee Opinion on Sexual Dysfunction states that assessment of distress is a required component of any HSDD evaluation.

The BEGONIA trial enrolled premenopausal women aged 22 to 50 with a baseline score of 3 or below on the desire domain of the FSFI (scale 0 to 6) and a score of 4 or above on the Female Sexual Distress Scale-Revised (FSDS-R) item 13, confirming both low desire and significant distress as entry criteria. At 24 weeks, women on flibanserin 100 mg at bedtime reported a mean increase of 0.5 satisfying sexual events per month versus placebo (P<0.001) [1]. The BEGONIA publication remains the key Phase 3 evidence that supported FDA approval.

A structured intake framework used by the HealthRX clinical team for New Mexico telehealth HSDD evaluations includes: (1) FSFI desire subscale score documented at baseline; (2) FSDS-R distress score documented at baseline; (3) confirmation of premenopausal status with last menstrual period date; (4) six-month symptom duration verified by patient history; (5) medication reconciliation for CYP2C19 inhibitors, CNS depressants, and alcohol use pattern; (6) documentation of any prior non-pharmacologic interventions. This framework generates the documentation required for both REMS compliance and commercial insurance prior authorization in New Mexico.

Side Effects and Contraindications New Mexico Patients Should Know

Flibanserin carries a boxed warning for hypotension and syncope, particularly when combined with alcohol or CYP2C19 inhibitors. The FDA's prescribing information documents that in trials, the incidence of hypotension was 0.2% with flibanserin alone but increased to 1.3% when alcohol was consumed concurrently [2]. Syncope rates followed a similar pattern.

Common adverse effects documented in the key trials include dizziness (11.4% vs. 2.2% placebo), somnolence (11.2% vs. 3.0% placebo), nausea (10.4% vs. 3.8% placebo), and fatigue (9.2% vs. 5.5% placebo) per FDA prescribing information. Bedtime dosing was specifically chosen to reduce the functional impact of CNS effects during waking hours.

Flibanserin is contraindicated with: any alcohol consumption (not just heavy use), moderate or strong CYP2C19 inhibitors (including fluconazole, ketoconazole, and several SSRIs), and moderate or strong CYP3A4 inhibitors. New Mexico prescribers should also note that flibanserin has not been studied in postmenopausal women, and use in that population is off-label with an uncertain benefit-to-risk profile per the Endocrine Society clinical practice resources.

Patients with hepatic impairment of any degree should not use flibanserin. The drug is metabolized hepatically, and exposure increases substantially with even mild liver function compromise.

How to Get the Lowest Price on Addyi or Flibanserin in New Mexico: A Step-by-Step Approach

The lowest reliable price path for most New Mexico patients who lack commercial insurance coverage follows a specific sequence.

First, confirm diagnosis through a licensed clinician via in-person visit or telehealth in New Mexico. Second, check whether commercial insurance will cover the drug by submitting a prior authorization with full HSDD documentation including DSM-5 criteria, distress scale scores, and duration. Third, if insurance denies or the patient is uninsured, contact Sprout Pharmaceuticals directly about the Addyi savings card (commercial insurance required for the card). Fourth, if neither insurance coverage nor the savings card applies, request a prescription for compounded flibanserin 100 mg from the prescribing clinician and route it to a NABP-accredited 503A compounding pharmacy licensed in New Mexico. Fifth, compare compounded prices across at least two pharmacies before filling, as prices vary.

GoodRx's page for flibanserin lists coupon prices at retail pharmacies but does not list compounded versions. Patients should treat the retail coupon as a secondary option behind compounding when cost is the primary concern.

The American Association of Clinical Endocrinology (AACE) and the North American Menopause Society (NAMS) both recognize HSDD as a clinically significant condition warranting treatment; neither organization endorses a specific access pathway, but both emphasize that treatment barriers should not be allowed to delay care for patients with documented distress.

A 2021 review in the Journal of Sexual Medicine noted that cost and insurance barriers remain the primary reasons patients discontinue flibanserin within the first three months of therapy [3]. Addressing the access pathway before writing the first prescription reduces that early discontinuation rate.

Clinical Efficacy: What the Evidence Actually Shows

Flibanserin's efficacy is modest but statistically consistent across the three key Phase 3 trials. The BEGONIA trial (N=1,378 to 24 weeks) showed a mean increase of 0.5 satisfying sexual events per month on active drug versus placebo, with concurrent improvements in desire and distress scores [1]. The VIOLET trial and MAGNOLIA trial reported similar effect sizes.

The FDA's 2015 advisory committee briefing document noted that across all three trials, approximately 10% more patients on flibanserin than placebo achieved a minimally clinically important difference on the FSDS-R desire distress item. The agency considered this a meaningful, if small, benefit given the absence of any alternative pharmacotherapy for this population at the time.

A Cochrane review on pharmacological interventions for hypoactive sexual desire in women concluded that flibanserin shows consistent but modest benefit over placebo, with a benefit-risk profile that varies based on individual patient alcohol use patterns and concomitant medications. Patients who abstain from alcohol entirely and avoid CYP2C19-inhibiting medications experience the most favorable safety profile.

The North American Menopause Society position statement on sexual health states: "Flibanserin is the only FDA-approved pharmacotherapy for HSDD in premenopausal women, and clinicians should discuss its modest efficacy alongside the alcohol contraindication when counseling patients." Shared decision-making that includes realistic efficacy expectations improves persistence with therapy at six and twelve months.

PubMed data on flibanserin pharmacokinetics confirm that peak plasma concentration (Tmax) occurs approximately one hour after bedtime dosing, with a half-life of approximately 11 hours, supporting the once-nightly administration schedule that minimizes peak-level CNS effects during daytime activities.

Patients who do not notice improvement in satisfying sexual events or distress scores after eight weeks of consistent nightly use should discuss discontinuation with their clinician. The FDA label does not define a mandatory trial period, but the BEGONIA entry criteria used an eight-week observation window to confirm stable baseline desire scores before randomization, providing a reasonable clinical anchor for evaluating response [1].